MS-DRG · FY 2026 v43.0

MS-DRG 838 – Chemotherapy with Acute Leukemia as Secondary Diagnosis with CC or High Dose Chemotherapy Agent

A Medical DRG in MDC 17 (Myeloproliferative Diseases & Disorders, Poorly Differentiated Neoplasms). Inpatient cases group to DRG 838 when the ICD-10-CM principal diagnosis is one of the 36 codes listed below. Its FY 2026 relative weight is 2.0874 with a geometric mean length of stay of 5.1 days.

Medical DRG – assigned by principal diagnosis✓ Official CMS v43.0 dataset
2.0874
Relative Weight
5.1
Geometric Mean LOS (days)
6.7
Arithmetic Mean LOS (days)
36
Principal Diagnosis Codes
10
Procedure Codes
How a case is assigned to DRG 838

The grouper first assigns the case to MDC 17 from the principal diagnosis and finds no qualifying operating-room procedure (this is a Medical DRG; ICD-10-PCS codes do not drive assignment here).

ICD-10-CM

Principal Diagnosis Codes 36 codes · 7 categories

36 of 36 shown
C91 Lymphoid leukemia3 codes
  • C91.00 Acute lymphoblastic leukemia not having achieved remission
  • C91.01 Acute lymphoblastic leukemia, in remission
  • C91.02 Acute lymphoblastic leukemia, in relapse
C92 Myeloid leukemia15 codes
  • C92.00 Acute myeloblastic leukemia, not having achieved remission
  • C92.01 Acute myeloblastic leukemia, in remission
  • C92.02 Acute myeloblastic leukemia, in relapse
  • C92.40 Acute promyelocytic leukemia, not having achieved remission
  • C92.41 Acute promyelocytic leukemia, in remission
  • C92.42 Acute promyelocytic leukemia, in relapse
  • C92.50 Acute myelomonocytic leukemia, not having achieved remission
  • C92.51 Acute myelomonocytic leukemia, in remission
  • C92.52 Acute myelomonocytic leukemia, in relapse
  • C92.60 Acute myeloid leukemia with 11q23-abnormality not having achieved remission
  • C92.61 Acute myeloid leukemia with 11q23-abnormality in remission
  • C92.62 Acute myeloid leukemia with 11q23-abnormality in relapse
  • C92.A0 Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
  • C92.A1 Acute myeloid leukemia with multilineage dysplasia, in remission
  • C92.A2 Acute myeloid leukemia with multilineage dysplasia, in relapse
C93 Monocytic leukemia3 codes
  • C93.00 Acute monoblastic/monocytic leukemia, not having achieved remission
  • C93.01 Acute monoblastic/monocytic leukemia, in remission
  • C93.02 Acute monoblastic/monocytic leukemia, in relapse
C94 Other leukemias of specified cell type9 codes
  • C94.00 Acute erythroid leukemia, not having achieved remission
  • C94.01 Acute erythroid leukemia, in remission
  • C94.02 Acute erythroid leukemia, in relapse
  • C94.20 Acute megakaryoblastic leukemia not having achieved remission
  • C94.21 Acute megakaryoblastic leukemia, in remission
  • C94.22 Acute megakaryoblastic leukemia, in relapse
  • C94.40 Acute panmyelosis with myelofibrosis not having achieved remission
  • C94.41 Acute panmyelosis with myelofibrosis, in remission
  • C94.42 Acute panmyelosis with myelofibrosis, in relapse
C95 Leukemia of unspecified cell type3 codes
  • C95.00 Acute leukemia of unspecified cell type not having achieved remission
  • C95.01 Acute leukemia of unspecified cell type, in remission
  • C95.02 Acute leukemia of unspecified cell type, in relapse
Z08 Encounter for follow-up examination after completed treatment for malignant neoplasm1 code
  • Z08 Encounter for follow-up examination after completed treatment for malignant neoplasm
Z51 Encounter for other aftercare and medical care2 codes
  • Z51.11 Encounter for antineoplastic chemotherapy
  • Z51.12 Encounter for antineoplastic immunotherapy
ICD-10-PCS

Procedure Codes 10 codes · 6 categories

3E03 Administration, Physiological Systems and Anatomical Regions, Introduction2 codes
  • 3E03002 Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach
  • 3E03302 Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
3E04 Administration, Physiological Systems and Anatomical Regions, Introduction2 codes
  • 3E04002 Introduction of High-dose Interleukin-2 into Central Vein, Open Approach
  • 3E04302 Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach
3E05 Administration, Physiological Systems and Anatomical Regions, Introduction2 codes
  • 3E05002 Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach
  • 3E05302 Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
3E06 Administration, Physiological Systems and Anatomical Regions, Introduction2 codes
  • 3E06002 Introduction of High-dose Interleukin-2 into Central Artery, Open Approach
  • 3E06302 Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach
3E0R Administration, Physiological Systems and Anatomical Regions, Introduction1 code
  • 3E0R302 Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach
3E0S Administration, Physiological Systems and Anatomical Regions, Introduction1 code
  • 3E0S302 Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach
ICD-10-CM

Severity Exclusions 33 codes

When a case groups to DRG 838, these secondary diagnoses do not count as a CC or MCC for the severity split.

View excluded secondary diagnoses33
  • C91.00 Acute lymphoblastic leukemia not having achieved remission
  • C91.01 Acute lymphoblastic leukemia, in remission
  • C91.02 Acute lymphoblastic leukemia, in relapse
  • C92.00 Acute myeloblastic leukemia, not having achieved remission
  • C92.01 Acute myeloblastic leukemia, in remission
  • C92.02 Acute myeloblastic leukemia, in relapse
  • C92.40 Acute promyelocytic leukemia, not having achieved remission
  • C92.41 Acute promyelocytic leukemia, in remission
  • C92.42 Acute promyelocytic leukemia, in relapse
  • C92.50 Acute myelomonocytic leukemia, not having achieved remission
  • C92.51 Acute myelomonocytic leukemia, in remission
  • C92.52 Acute myelomonocytic leukemia, in relapse
  • C92.60 Acute myeloid leukemia w 11q23-abnormality not achieve remis
  • C92.61 Acute myeloid leukemia with 11q23-abnormality in remission
  • C92.62 Acute myeloid leukemia with 11q23-abnormality in relapse
  • C92.A0 Acute myeloid leuk w multilin dysplasia, not achieve remis
  • C92.A1 Acute myeloid leukemia w multilin dysplasia, in remission
  • C92.A2 Acute myeloid leukemia w multilineage dysplasia, in relapse
  • C93.00 Acute monoblastic/monocytic leukemia, not achieve remission
  • C93.01 Acute monoblastic/monocytic leukemia, in remission
  • C93.02 Acute monoblastic/monocytic leukemia, in relapse
  • C94.00 Acute erythroid leukemia, not having achieved remission
  • C94.01 Acute erythroid leukemia, in remission
  • C94.02 Acute erythroid leukemia, in relapse
  • C94.20 Acute megakaryoblastic leukemia not achieve remission
  • C94.21 Acute megakaryoblastic leukemia, in remission
  • C94.22 Acute megakaryoblastic leukemia, in relapse
  • C94.40 Acute panmyelosis w myelofibrosis not achieve remission
  • C94.41 Acute panmyelosis with myelofibrosis, in remission
  • C94.42 Acute panmyelosis with myelofibrosis, in relapse
  • C95.00 Acute leukemia of unsp cell type not achieve remission
  • C95.01 Acute leukemia of unspecified cell type, in remission
  • C95.02 Acute leukemia of unspecified cell type, in relapse

Frequently Asked Questions

What is MS-DRG 838?

MS-DRG 838 (Chemotherapy with Acute Leukemia as Secondary Diagnosis with CC or High Dose Chemotherapy Agent) is a medical DRG in MDC 17 (Myeloproliferative Diseases & Disorders, Poorly Differentiated Neoplasms). Its FY 2026 relative weight is 2.0874 with a geometric mean length of stay of 5.1 days.

How many diagnosis codes group to DRG 838?

36 ICD-10-CM principal diagnosis codes group to this DRG, spanning 7 three-character categories.

What is the relative weight of DRG 838?

The FY 2026 relative weight of this DRG is 2.0874, meaning reimbursement of roughly 2.09 times the average Medicare inpatient case. Multiply by a hospital's blended base rate for the approximate payment.

← PreviousDRG 837 – Chemotherapy with Acute Leukemia as Secondary Diagnosis or
Source: CMS ICD-10 MS-DRG v43.0 Definitions Manual and the FY 2026 IPPS Final Rule (Table 5), effective October 1, 2025 through September 30, 2026. We publish the DRG assignments as CMS defines them and add the navigation, search, and code links.